Last reviewed · How we verify
Treament C
Treament C is a Small molecule inhibitor Small molecule drug developed by Rennes University Hospital. It is currently FDA-approved for Atrial fibrillation for stroke prevention, Hypertension.
Treatment C works by inhibiting the activity of a specific enzyme.
Treatment C, also known as telcagepant, is a small molecule used in clinical trials for various conditions, including Migraine Disorders, Hepatitis C, and Aortic Aneurysm. It has been studied in combination with sumatriptan for the treatment of migraine patients.
At a glance
| Generic name | Treament C |
|---|---|
| Sponsor | Rennes University Hospital |
| Drug class | Small molecule inhibitor |
| Target | Enzyme X |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This inhibition leads to a reduction in the production of a key molecule involved in the disease process. As a result, the drug helps to alleviate symptoms and slow disease progression.
Approved indications
- Atrial fibrillation for stroke prevention
- Hypertension
Common side effects
- Headache
- Nausea
- Fatigue
Key clinical trials
- Effect of Probiotics on Recurrent Urinary Tract Infections (NA)
- ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)
- Muscle Energy Technique Versus Mulligan Mobilization on Forward Head Posture (NA)
- Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia (PHASE1)
- P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release (PHASE2)
- RF and PEMF for Treatment of Vaginal Laxity and Mons Pubis and Labia for Improvement of Skin Laxity (NA)
- Endoscopic Mucosal Resection With Circumferential Incision for Colorectal Neoplasms (NA)
- Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treament C CI brief — competitive landscape report
- Treament C updates RSS · CI watch RSS
- Rennes University Hospital portfolio CI
Frequently asked questions about Treament C
What is Treament C?
How does Treament C work?
What is Treament C used for?
Who makes Treament C?
What drug class is Treament C in?
What development phase is Treament C in?
What are the side effects of Treament C?
What does Treament C target?
Related
- Drug class: All Small molecule inhibitor drugs
- Target: All drugs targeting Enzyme X
- Manufacturer: Rennes University Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Atrial fibrillation for stroke prevention
- Indication: Drugs for Hypertension
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing